A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope
Swetha Raman, Samantha N. Buongervino, Maria Lane, Doncho V. Zhelev, Zhongyu Zhu, Hong Cui, Benjamin Martinez, Daniel Martínez, Yanping Wang, Kristen Upton, Khushbu Patel, Komal S. Rathi, Carmen Navia, Daniel B. Harmon, Yimei Li, Bruce Pawel, Dimiter S. Dimitrov, John M. Maris, Jean‐Philippe Julien, Kristopher R. Bosse
Abstract
toxicity. These studies provide preclinical data to support the clinical translation of ADCs targeting GPC2.
Topics & Concepts
NeuroblastomaEpitopeCancer researchAntibody-drug conjugateAntibodyBiologyIn vivoChemistryMonoclonal antibodyMolecular biologyCell cultureImmunologyGeneticsBiotechnologyNeuroblastoma Research and TreatmentsLung Cancer Research StudiesNeuroendocrine Tumor Research Advances